AFFYMAX INC Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2013-08-20: Form 8-K; Period of report 2013-08-15; Description 1.01 Entry into a Material Definitive Agreement; Details 1.01.
- 2013-08-16: Form 8-K; Period of report 2013-08-15; Description 8.01 Other Events; Details 8.01.
- 2013-06-07: Form 8-K; Period of report 2013-06-04; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders; Details 1.01.
- 2013-05-31: Form 8-K; Period of report 2013-05-28; Description 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; Details 1.01.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2013-08-20 | 8-K | 2013-08-15 | 1.01 Entry into a Material Definitive Agreement | 1.01 On August 15, 2013, Affymax, Inc. (the “Company”) executed a Seventh Amendment to Lease, dated as of August 14, 2013 and effective as of August 15, 2013 (the “Seventh Amendment”), with CA-Foothill Research Center L.P. (“Landlord”), which provides for the acceleration of the termination date of the lease agreement for the Company’s offices and laboratories located at 4001 Miranda Avenue, 4009 Miranda Avenue and 4015 Miranda Avenue, in Palo Alto, California, dated as of May 30, 1990 (the “Lease Agreement”), as amended by amendments one through six. | a13-19007_18k.htm |
| 2013-08-16 | 8-K | 2013-08-15 | 8.01 Other Events | 8.01 The Brenner Group, Inc. (“TBG”) was retained by the Board of Directors of Affymax, Inc. (the “Company”) to lead the Company through a necessary restructure in the face of the OMONTYS recall. | a13-17850_28k.htm |
| 2013-06-07 | 8-K | 2013-06-04 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 5.07 Submission of Matters to a Vote of Security Holders | 1.01 Entry into a Material Definitive Agreement. 1.02 The information set forth under Item 1.01 of this Current Report on Form 8-K is hereby incorporated into this Item 1.02 by reference. 3.01 As previously disclosed, on May 28, 2013, the Company received a determination letter (the “Determination Letter”) from the Nasdaq Stock Market LLC (“Nasdaq”) indicating Nasdaq’s belief that the Company should be delisted from Nasdaq, and that absent an appeal, trading in the Company’s common stock would be suspended at the opening of business on June 6, 2013, and a Form 25-NSE would be filed with the Securities and Exchange Commission to remove the Company’s securities from listing and registration on Nasdaq. 5.02 On June 4 and June 5, 2013, Ted W. Love, M.D., Kathleen LaPorte and Keith R. Leonard, Jr. notified the Company of their resignation as directors of the Company. 5.07 On June 6, 2013, the Company held its Annual Meeting of Stockholders (the “Meeting”) at 4009 Miranda Avenue, Palo Alto, CA 94304. | a13-14566_18k.htm |
| 2013-05-31 | 8-K | 2013-05-28 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. 1.02 The information set forth under Item 1.01 of this Current Report on Form 8-K is hereby incorporated into this Item 1.02 by reference. | a13-14193_28k.htm |
| 2013-05-31 | 8-K | 2013-05-28 | 8.01 Other Events | a13-14193_18k.htm | |
| 2013-05-15 | 8-K/A | 2013-05-14 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 On May 14, 2013, the Board of Directors of Affymax, Inc (the “Company”) approved an amendment to the Company’s 2006 Equity Incentive Plan to eliminate the automatic initial and annual equity grants to non-employee directors, effective immediately. 5.02 As previously disclosed, the Company has retained The Brenner Group, Inc. (“TBG”), an experienced restructuring firm, to provide restructuring support and related management services in order to implement a company-wide restructuring plan. | a13-12446_18ka.htm |
| 2013-05-14 | 8-K | 2013-05-14 | 1.01 Entry into a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 1.01 On June 14, 2013, the Board of Directors of Affymax, Inc (the “Company”) approved an amendment to the Company’s 2006 Equity Incentive Plan to eliminate the automatic initial and annual equity grants to non-employee directors, effective immediately. 5.02 As previously disclosed, the Company has retained The Brenner Group, Inc. (“TBG”), an experienced restructuring firm, to provide restructuring support and related management services in order to implement a company-wide restructuring plan. | a13-12446_18k.htm |
| 2013-04-23 | 8-K | 2013-04-19 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On April 19, 2013, Affymax, Inc (the “Company”) entered into a Consulting Engagement Agreement (the “Agreement”) with The Brenner Group, Inc. (“TBG”), an experienced restructuring firm, to provide restructuring support and related management services in order to implement a company-wide restructuring plan. | a13-10633_18k.htm |
| 2013-04-10 | 8-K | 2013-04-09 | 1.01 Entry into a Material Definitive Agreement; 1.02 Termination of a Material Definitive Agreement; 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT; AND ITEM 1.02 TERMINATION OF A MATERIAL DEFINITIVE AGREEMENT. 5.02 As previously disclosed, on March 18, 2013, the Company announced a reduction in force of approximately 75% of its workforce. | a13-9904_18k.htm |
| 2013-04-04 | 8-K | 2013-04-03 | 1.02 Termination of a Material Definitive Agreement | 1.02 On April 3, 2013, we entered into a letter agreement, or Letter Agreement, relating to the loan and security agreement dated March 26, 2012, or the Loan Agreement, with Oxford Finance Corporation and Silicon Valley Bank, or, collectively, the Lenders. | a13-9500_18k.htm |
| 2013-04-02 | 8-K | 2013-04-02 | 2.02 Results of Operations and Financial Condition | 2.02 On April 2, 2013, Affymax, Inc. issued a press release announcing its financial results for the quarterly period and fiscal year ended December 31, 2012. | a13-7774_48k.htm |
| 2013-03-18 | 8-K | 2013-03-18 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; 8.01 Other Events | 5.02 On March 18, 2013, in connection with a reduction in force of approximately 75% of its workforce, Affymax, Inc. (the “Company”) will be terminating the employment of Jeffrey Knapp, the Chief Commercial Officer, along with the commercial and medical affairs field forces as well as other officers and employees throughout the organization. 8.01 In early February 2013 and in consultation with the U.S. Food and Drug Administration (FDA), the Company and Takeda, voluntarily recalled OMONTYS® nationwide from the market as a result of post-marketing reports regarding serious hypersensitivity reactions, including anaphylaxis, which can be life-threatening or fatal. | a13-7774_18k.htm |
| 2013-03-01 | 8-K | 2013-02-27 | 8.01 Other Events | 8.01 On February 27, 2013, a securities class action lawsuit was commenced in the United States District Court for the Northern District of California, naming as defendants Affymax, Inc. (“the Company”), certain of its officers, Takeda Pharmaceutical Company Limited, Takeda Pharmaceuticals U.S.A., Inc. and Takeda Global Research & Development Center, Inc. The lawsuit, brought on behalf of a purported stockholder of the Company, alleges violations of the Securities Exchange Act of 1934 in connection with allegedly false and misleading statements made by the defendants regarding the Company’s business practices, financial projections and other disclosures between December 8, 2011 and February 22, 2013 (the “Class Period”). | a13-6406_18k.htm |
| 2013-02-25 | 8-K | 2013-02-23 | 8.01 Other Events | 8.01 On February 23, 2013, Affymax, Inc. (the “Company”) and Takeda Pharmaceutical Company Limited (“Takeda”) announced a nationwide voluntary recall of OMONTYS® (peginesatide) Injection as a result of new postmarketing reports regarding serious hypersensitivity reactions, including anaphylaxis which can be life-threatening or fatal. | a13-5959_18k.htm |
| 2013-02-14 | 8-K | 2013-02-13 | 8.01 Other Events | 8.01 On February 13, 2013, Fresenius Medical Care North America (“FMCNA”) communicated that it has accumulated experience with OMONTYS® (peginesatide) Injection in more than 56,600 administrations in over 18,000 patients in its dialysis facilities and that it will pause further expansion of the OMONTYS pilot that began in late July 2012. | a13-5217_18k.htm |
| 2013-02-05 | 8-K | 2013-02-04 | 8.01 Other Events | 8.01 On February 4, 2013, Takeda Pharmaceutical Company Limited (“Takeda”) announced, in its “Consolidated Financial Results for the Nine Month Period Ended December 31, 2012” webcast, net product sales of OMONTYS® (peginesatide) Injection for the nine month period ended December 31, 2012 of 2.8 billon yen. | a13-4480_18k.htm |
| 2013-02-01 | 8-K | 2013-01-30 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 30, 2013, based on the recommendation of the Compensation Committee, the Board of Directors (the “Board”) of Affymax, Inc. (the “Company”) approved certain annual compensation decisions and amendments to certain employment agreements to, among other things, remove change-in-control gross-up payments. | a13-4206_18k.htm |